# US 2025/0144104 A1 · Discovery of a new inhibitor for the yth domain-containing m6a rna readers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144104 A1
- Document ID: US20250144104A1
- Status: Published application
- Kind: A1
- Application number: 18/937,951
- Filed: 2024-11-05
- Published: 2025-05-08
- Earliest claimed: 2023-11-06
- Assignees: The Trustees of Boston College
- Applicants: The Trustees of Boston College
- Inventors: Huiqing Zhou; Chuan-Hui Wang
- Web page: https://patentgrep.com/patent/US20250144104A1

## CPC

- A61K 31/52: Purines, e.g. adenine
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- C12N 15/1062: {mRNA-Display, e.g. polypeptide and encoding template are connected covalently}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention discloses a method for inhibiting a pan-YTH domain by contacting the pan-YTH domain with a small molecule pan-YTH domain inhibitor. Novel methods of locating the small molecule inhibitors are discussed for high-throughput screening (HTS). The small molecule pan-YTH domain inhibitor is designed to inhibit multiple YTH domains present in a YTH family of proteins that identify m6A-modified transcripts, thereby altering the post-transcriptional modification process.

## Claims

### Claim 1

A method for inhibiting a pan-YTH domain by contacting the domain with a small molecule inhibitor comprising Formula 1:
and/or a pharmaceutically acceptable salt thereof, hydrate and/or solvate thereof, tautomer thereof, and/or a prodrug thereof of Formula 1;
wherein each independent occurrence of A and/or B is independently selected from and/or comprises one or more of the following substituents and/or a salt, tautomer, hydrate and/or solvate thereof:
wherein each independent occurrence of is a linker to Formula 1 and represents an attachment to an atom as indicated in Formula 1 and includes or is a combination of a single bond (−), a bond to a nitrogen, a bond to a carbon, a bond to an oxygen (—O—), a double bond (=), a triple bond (≡) or (—C2H2—), a bond to C—C, a bond to C—N, —(CH2)n—, wherein independently each n=0, 1, 2, 3, 4, 5, 6, 7, 8, or 9; or a combination thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the method can inhibit the interaction between YTH domains and m6A-modified transcripts.

### Claim 3 (depends on 1)

The method of claim 1, wherein a YTH domain is part of the YTH family of proteins.

### Claim 4 (depends on 1)

The method of claim 1, wherein the small molecule comprises:

### Claim 5

A method for identifying pan-YTH domain inhibitors, the method comprising the steps of
(1) contacting an YTH domain of the YTHDF1 protein and FAM-labeled m6A RNA with a candidate inhibitor; and
(2) executing FP HTS (fluorescence polarization, high-throughput screening) on the candidate inhibitor; whereby a potential inhibition provided by the candidate is indicated.

### Claim 6 (depends on 5)

The method of claim 5, wherein the candidate inhibitor is a small molecule compound selected from a library of diverse chemical structures.

### Claim 7 (depends on 5)

The method of claim 5, wherein the FP HTS assay measures the binding affinity between the YTH domain and the candidate inhibitor by detecting changes in fluorescence polarization upon binding of a fluorescently labeled probe to the YTH domain in the presence or absence of the candidate inhibitor.

### Claim 8 (depends on 5)

The method of claim 5, further comprising the step of validating the lead inhibitor in a cell-based assay to confirm inhibition of the YTH domain by measuring changes in m6A-modified mRNA levels or translation efficiency.

### Claim 9 (depends on 5)

The method of claim 5, further comprising the step of determining the selectivity of the lead inhibitor by testing its ability to inhibit other YTH domain-containing proteins or unrelated RNA-binding proteins.

### Claim 10 (depends on 5)

The method of claim 5, further comprising the step of optimizing the lead inhibitor by synthesizing and testing analogs with improved potency, selectivity, or pharmacokinetic properties.

### Claim 11 (depends on 5)

The method of claim 5, wherein the FP HTS assay is performed in a high-throughput format using 384-well or 1536-well microplates to screen a large number of candidate inhibitors simultaneously.

### Claim 12 (depends on 5)

The method of claim 5, wherein the lead inhibitor is further characterized by determining its binding mode and molecular interactions with the YTH domain using X-ray crystallography or NMR spectroscopy.

### Claim 13 (depends on 5)

The method of claim 5, wherein the lead inhibitor is used as a tool compound to study the biological functions of the YTHDF1 protein and the role of m6A modification in post-transcriptional gene regulation.

### Claim 14

A method of treating a disease or disorder, comprising:
contacting a pan-YTH domain in a subject with a small molecule pan-YTH domain inhibitor, wherein the small molecule pan-YTH domain inhibitor is capable of inhibiting multiple YTH domains found in a YTH family of proteins that recognize m6A-modified transcripts, thereby changing a post-transcriptional modification process.

### Claim 15 (depends on 14)

The method of claim 14, wherein the disease or disorder is selected from the group consisting of cancer, viral infections, bacterial infections, fungal infections, parasitic infections, inflammatory disorders, autoimmune disorders, neurodegenerative disorders, metabolic disorders, cardiovascular disorders, respiratory disorders, and genetic disorders.

### Claim 16 (depends on 14)

The method of claim 14, wherein the cancer is selected from the group consisting of leukemia, lymphoma, melanoma, lung cancer, breast cancer, colorectal cancer, prostate cancer, ovarian cancer, and brain cancer.

### Claim 17 (depends on 14)

The method of claim 14, wherein the viral infection is selected from the group consisting of HIV, hepatitis B, hepatitis C, influenza, and COVID-19.

### Claim 18 (depends on 14)

The method of claim 14, wherein the inflammatory disorder is selected from the group consisting of rheumatoid arthritis, inflammatory bowel disease, psoriasis, and asthma.

### Claim 19 (depends on 14)

The method of claim 14, wherein the neurodegenerative disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis.

### Claim 20 (depends on 14)

The method of claim 14, wherein the metabolic disorder is selected from the group consisting of obesity, diabetes, and non-alcoholic fatty liver disease.